Shareholders Equity: The sum of preferred and common equity items.
Brainstorm Cell Therapeutics Inc. (BCLI) had Shareholders Equity of $-9.98M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-2.43M |
|
-- |
|
-- |
|
$2.24M |
|
$-2.24M |
|
$-0.19M |
|
$-2.43M |
|
$-2.43M |
|
$-2.43M |
|
$-2.43M |
|
$-2.43M |
|
$-2.43M |
|
$-2.24M |
|
$-2.20M |
|
9.27M |
|
9.27M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$0.31M |
|
$0.23M |
|
$0.71M |
|
$1.02M |
|
$11.01M |
|
-- |
|
-- |
|
$11.01M |
|
$-9.98M |
|
$-9.98M |
|
|
Shareholders Equity |
$-9.98M |
11.04M |
|
| Cash Flow Statement Financials | |
$-6.97M |
|
-- |
|
$6.88M |
|
$0.37M |
|
$0.28M |
|
$-0.10M |
|
$1.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.03 |
|
-- |
|
-- |
|
-- |
|
-0.10 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.97M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
24.38% |
|
24.38% |
|
-238.16% |
|
24.38% |
|
$-0.90 |
|
$-0.75 |
|
$-0.75 |
|